Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924313 · ClinicalTrials.gov registry record · Phase 1
Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00924313: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00924313 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00924313, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Background: * Prostate cancers are difficult to see on most imaging studies such as X-rays, computed tomography (CT) scans, conventional magnetic resonance imaging (MRI) scans and conventional positron emission tomography (PET) scans. * An experimental radioactive tracer called 11C-acetate accumulates in prostate tumor cells and may help find prostate cancers more accurately than other imaging methods. Objectives: * To determine the accuracy of prostate tumor imaging using the tracer 11C-acetate. Eligibility: * Patients 18 years of age and older who are undergoing surgery for localized prostate cancer at the National Institutes of Health (NIH) Clinical Center. Design: * Patients have a positron emission tomography (PET scan). For this test, an intravenous (IV) line is placed in the patient's arm and the patient lies on a table inside the donut shaped scanner. (11)C-acetate is injected into the vein through the catheter and images of the lower pelvis and abdomen are obtained over 30 minutes. * Patients have an endorectal coil MRI scan. For this test, a tube is placed in the rectum, just behind the prostate, to increase the amount of signal received by the magnetic resonance (MR) unit. Other coils may be wrapped around the pelvis to further improve the quality of the scan. The patient lies on the scanning table for about 75 to 90 minutes while images are obtained. During the scan, a contrast agent called gadolinium is injected through an intravenous (IV) line to brighten the images.
Interventions
- DRUG (C-11 Acetate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09-10 |
| Est. Completion | 2011-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924313
The ClinicalTrials.gov registry entry for NCT00924313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which (C-11 Acetate) is the first listed.
NCT00924313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924313 about?
NCT00924313 is a clinical study titled "Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer". Background: * Prostate cancers are difficult to see on most imaging studies such as X-rays, computed tomography (CT) scans, conventional magnetic resonance imaging (MRI) scans and conventional positron emission tomography (PET) scans. * An experimental radioactive tracer called 11C-acetate accumula...
What is the current status of trial NCT00924313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-09-10. Estimated completion is 2011-04-19.
What interventions are being tested in trial NCT00924313?
The interventions under investigation include: (C-11 Acetate) (DRUG).
Who is sponsoring clinical trial NCT00924313?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.